Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Preparation of the working viruses of B.1.1, Delta and Omicron SARS-CoV-2

ABSTRACT: To investigate the virological properties of SARS-CoV-2 variants, we amplified the clinical isolates of an early pandemic D614G-bearing isolate (B.1.1 lineage, strain TKYE610670; GISAID ID: EPI_ISL_479681), a Delta isolate (B.1.617.2 lineage, strain TKYTK1734; GISAID ID: EPI_ISL_2378732) and an Omicron isolate (BA.1 lineage, strain TY38-873; GISAID ID: EPI_ISL_7418017) and prepared the working viruses.

ORGANISM(S): Severe acute respiratory syndrome coronavirus 2

PROVIDER: GSE192472 | GEO | 2022/01/07

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

The Receptor Binding Domain of SARS-CoV-2 Omicron Subvariants Targets Siglec-9 to Decrease the Immunogenicity by Preventing Phagocytosis of Macrophages

Project description:SARS-CoV-2 Omicron infection results in a milder clinical feature compared to the Delta strain. The development of Omicron specific vaccine has also been hampered due to the low immunogenicity. By reverse-mutating the amino acids in the Omicron receptor binding domain (RBD), we identified that the mutation from Phenylalanine 375 (F375) in the Omicron spike to Serine 375 (S375) in Delta and other early strains significantly enhances the immune response in the manner of vaccines. Interestingly, the new evolution of the 371FAPF375FAF sequence in Omicron exhibited a potent inhibitory effect on macrophage uptake of the RBD nanoparticle or spike-pseudovirus particles. Omicron RBD enhances binding to Siglec-9 on macrophages to reduce the immunogenicity and increase the immune evasion, which could be abrogated by Serine 375 mutation. Based upon these observations, we further developed a bivalent Omicron RBD with S375 mutation and Delta RBD nanoparticle vaccine, which elicited potent and broad neutralizing antibodies in mice, rabbits, and rhesus macaques. Our research suggests that manipulating the Siglec-9 pathway could be a promising approach to enhancing vaccine response. Importantly, our findings suggest that Omicron subvariants have developed a new strategy to evade immune surveillance by impairing the phagocytosis and antigen presentation processes of macrophages.

2023-12-28 | GSE251973 | GEO

Preparation of the working viruses of B.1.1, Delta and Omicron SARS-CoV-2

Project description:Preparation of the working viruses of B.1.1, Delta and Omicron SARS-CoV-2

| PRJNA791622 | ENA

Immunological and Metabolic Characteristics of the Omicron Variants Infection

Project description:The Omicron variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first identified in November 2021 in South Africa, has initiated the 5th wave of global pandemics. Here, we systemically examined immunological and metabolic characteristics of Omicron variants infection. We found Omicron resisted to neutralizing antibody targeting receptor binding domain (RBD) of wild-type SARS-CoV-2. Omicron could not be neutralized by sera of Corona Virus Disease 2019 (COVID-19) convalescent individuals who were infected with the Delta variant. Through mass spectrometry on MHC-bound peptidomes, we found that the spike protein of the Omicron variants could generate additional CD8+ T cell epitopes, compared with Delta. These epitopes could induce robust CD8+ T cell responses. Moreover, we found booster vaccination increased the cross-memory CD8+ T cell responses against Omicron. Metabolic regulome analysis of Omicron-specific T cell showed a metabolic profile that promoted memory T cell responses. Consistently, a higher fraction of memory CD8+ T cells were found in Omicron stimulated peripheral blood mononuclear cells (PBMCs). In addition, CD147 was also a receptor for the Omicron variants, and CD147 antibody inhibited infection of Omicron. CD147-mediated Omicron infection in a human CD147 transgenic mouse model induced exudative alveolar pneumonia. Taken together, our data suggested that vaccination booster and receptor blocking antibody are two effective strategies against Omicron.

2023-03-11 | PXD037955 | Pride

Preparation of chimeric recombinant SARS-CoV-2

Project description:To investigate the virological properties of a SARS-CoV-2 variant, Omicron BA.2, we generated chimeric recombinant viruses that express GFP and encodes the S gene of B.1.1 (ancestral D614G-bearing virus), Delta, BA.1 and BA.2. To verify the genome sequence of the working viruses, we performed viral RNA-sequencing of the viral stock.

2022-02-16 | GSE196649 | GEO

Prior vaccination exceeds prior infection in eliciting innate and humoral immune responses in Omicron infected outpatients

Project description:Antibody response following Omicron infection is reported to be less robust than that to other variants. Here we investigated how prior vaccination and/or prior infection modulates that response. Disease severity, antibody responses and immune transcriptomes were characterized in four groups of Omicron-infected outpatients (n=83): unvaccinated/no prior infection, vaccinated/no prior infection, unvaccinated/prior infection and vaccinated/prior infection. The percentage of patients with asymptomatic or mild disease was highest in the vaccinated/no prior infection group (87%) and lowest in the unvaccinated/no prior infection group (47%). Significant anti-Omicron spike antibody levels and neutralizing activity were detected in the vaccinated group immediately after infection but were not present in the unvaccinated/no prior infection group. Within two weeks, antibody levels against Omicron, increased. Omicron neutralizing activity in the vaccinated group exceeded that of the prior infection group. No increase in neutralizing activity in the unvaccinated/no prior infection group was seen. The unvaccinated/prior infection group showed an intermediate response. We then investigated the early transcriptomic response following Omicron infection in these outpatient populations and compared it to that found in unvaccinated hospitalized patients with Alpha infection. Omicron infected patients showed a gradient of transcriptional response dependent upon whether or not they were previously vaccinated or infected. Vaccinated patients showed a significantly blunted interferon response as compared to both unvaccinated Omicron infected outpatients and unvaccinated Alpha infected hospitalized patients typified by the response of specific gene classes such as OAS and IFIT that control anti-viral responses and IFI27, a predictor of disease outcome.

2022-06-11 | GSE201530 | GEO

Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron

Project description:Heterologous ChAdOx1-BNT162b2 vaccination induces a stronger immune response than BNT162b2-BNT162b2. Here we investigated the molecular transcriptome, germline allelic variants of immunoglobulin loci, and anti-Omicron antibody levels in 46 office and lab workers from the Republic of Korea following ChAdOx1-BNT162b2 vaccination. Anti-spike-specific IgG antibody levels against the ancestral SARS-CoV-2 strain increased from 70 AU/ml to 14,000 AU/ml to 142,000 AU/ml one, three and seven days following the second vaccination. Titers against VOC, including Omicron, were two- to three-fold lower, yet higher than those measured following BNT162b2-BNT162b2 vaccination. RNA-seq of peripheral immune cells demonstrated activation of interferon pathways with increased IGHV clonal transcripts encoding neutralizing antibodies. scRNA-seq revealed enriched B cell and CD4+ T cell responses in both ChAdOx1-BNT162b2 and BNT162b2-BNT162b2 recipients, but a stronger clonal expansion of memory B cells with ChAdOx1-BNT162b2. In summary, heterologous ChAdOx1-BNT162b2 provides an innate and adaptive immune response that exceeds homologous BNT162b2 vaccination.

2022-05-20 | GSE201535 | GEO

Single-cell sequencing of BALF from critial Omicron patients reveals the immune and inflammatory landscape

Project description:Immune characteristics associated with the SARS-CoV-2 Omicron variant of critical-ill patients are currently unclear. Severe disease has been associated with reconfiguration in the immune activity of the lung. Here we investigated the immune cell characteristics including myeloid cells, lymphocytes and alveolar epithelial cells in the bronchoalveolar lavage fluid (BALF) of 26 critical mechanical ventilation-required patients. The whole alveolar microenvironment of critical Omicron manifested apparent heterogeneous proinflammatory and interferon-stimulated gene (ISG) signature. CXCL5+ macrophages, VCAN+ macrophages, PI3+ neutrophils and CST7+ neutrophils contributed to the most proinflammatory phenotypes and were positively correlated with disease severity whereas ISG15+ neutrophils and CXCL10+ macrophages contributed to the most ISG phenotype and were negatively correlated with disease severity. Lymphocyte subsets were rare manifesting the lymphopenia in the alveoli and these lymphocyte subsets did not express substantial proinflammatory cytokines. Four different epithelial cell subsets were observed in BALF. The percentages of ISG15+ neutrophils were accompanied by more protective alveolar epithelial cells and may serve as the reshaping of exhaustive phenotype for CD4+ T cells. The CXCL10+ macrophages may promote plasmablast/plasma cell survival and activation. This atlas reveals a potential immune landscape in the bronchoalveolar microenvironment for severe and critical Omicron disease.

2024-08-26 | GSE263469 | GEO

Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.

Project description: Not available

| S-EPMC9707647 | biostudies-literature

Whole-genome sequencing of SARS-CoV-2 samples in Sweden during early 2022

Project description:We developed an extraction-free qPCR assay to identify Omicron BA.1 cases and verified lineage by sequencing. We find that BA.2 variants show almost twice the viral load (Ct) compared to both BA.1 as well as Delta variants.

2022-05-25 | E-MTAB-11650 | biostudies-arrayexpress

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection.

Project description: Not available

| S-EPMC9762743 | biostudies-literature